ContentsSynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyDrug Reaction DataReferencesView all Images (18)
Anti-TNF-alpha-induced eruptions
Print
Other Resources UpToDate PubMed

Anti-TNF-alpha-induced eruptions

Print Images (18)
Contributors: Vivian Wong MD, PhD, Susan Burgin MD
Other Resources UpToDate PubMed

Synopsis

Anti-tumor necrosis factor (TNF)-alpha therapies (etanercept, adalimumab, infliximab, certolizumab pegol [may be safe for use during pregnancy], golimumab, and their biosimilars) are used to treat various inflammatory conditions, including psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory bowel disease, and ankylosing spondylitis.

Several paradoxical cutaneous eruptions have been described with anti-TNF-alpha use, including:
  • Injection site reactions
  • Infusion reactions (with infliximab) – Both an acute hypersensitivity reaction within the first 2 hours and a delayed-type hypersensitivity reaction 1-14 days after the infusion.
  • Cutaneous infections – Various types of viral, bacterial, and fungal infections have been reported. Patients who are immunosuppressed, have other comorbidities, and/or are on higher doses of anti-TNF-alpha therapies may be at higher risk for infections.
  • Psoriasis – New-onset or exacerbated psoriasis has been reported. Palmoplantar pustular psoriasis is a common presentation, but plaque psoriasis is also reported.
  • Nonmelanoma skin cancer (NMSC) – The risk of NMSC may be increased, especially in those who are immunosuppressed.
  • Lupus-like syndrome – More common in patients who receive etanercept or infliximab. It typically resolves after anti-TNF-alpha therapy is stopped.
  • Lichen planus-like eruptions
  • Granulomatous reactions, including granuloma annulare and cutaneous and systemic sarcoidosis
  • Cutaneous vasculitis – The risk appears to be higher in patients with rheumatoid arthritis.
Rare reports of anti-TNF-alpha-induced alopecia, urticaria, atopic dermatitis, rosacea, folliculitis, oral swelling, oral ulcers, gingivitis, pityriasis rosea, erythema nodosum, neutrophilic eccrine hidradenitis, Sweet syndrome, granuloma annulare, vitiligo, and tongue discoloration have also been described. Erythema multiforme (EM) and Stevens-Johnson syndrome (SJS) / toxic epidermal necrolysis (TEN) have very rarely been described. The risk appears to be higher in female patients on TNF-alpha blockade for treatment of rheumatoid arthritis.

Codes

ICD10CM:
L27.0 – Generalized skin eruption due to drugs and medicaments taken internally

SNOMEDCT:
28926001 – Eruption caused by drug

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

The differentials for different cutaneous reactions are listed in the following diagnoses:

Best Tests

Subscription Required

Management Pearls

Subscription Required

Therapy

Subscription Required

Drug Reaction Data

Below is a list of drugs with literature evidence indicating an adverse association with this diagnosis. The list is continually updated through ongoing research and new medication approvals. Click on Citations to sort by number of citations or click on Medication to sort the medications alphabetically.

Subscription Required

References

Subscription Required

Last Reviewed: 12/20/2017
Last Updated: 10/11/2018
Copyright © 2020 VisualDx®. All rights reserved.
Anti-TNF-alpha-induced eruptions
Print 18 Images
View all Images (18)
(with subscription)
Anti-TNF-alpha-induced eruptions : Multiple skin lesions
Copyright © 2020 VisualDx®. All rights reserved.